Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (649)	5/7/1999 1:57:00 PM
From: Angelo	Respond to of 2344

StockMiser, You're not the only one waiting for a pull back on IMCL. Would you agree with me that there is going to be a correction in the Canadian and U.S. stock market in the near future.I think if that happen we should be able to pick shares of IMCL a lot cheapper. Angelo

To: StockMiser who wrote (649)	5/7/1999 3:44:00 PM
From: Dan Hamilton	Read Replies (1) \| Respond to of 2344

I have just started to follow Biomira, and I have a question relating to Biotechs in general. Obviously the further along a drug is in trials, the lower the risk to investors. Analysts typically try to do a risk adjusted rate of return calculation, discounting future potential profits by the number of years and probability of success/failure. I have seen statistics somewhere that suggest 2/3 of drugs that enter Phase I successfully pass, and 90% of those that pass Phase III ultimately get FDA approval. Does anyone know what the statistics are for Phase II and Phase III?

To: StockMiser who wrote (649)	5/7/1999 4:38:00 PM
From: Garry K.	Respond to of 2344

The recent annual report from Biomira IMHO has a distinct tone that differs from other years, particularly from Dr. Macpherson's commentary. I sence a tremendous amount of confidence in the pipeline of developments, especially the Theratope trial. I have always felt that Biomira has gone about their work in the most professional, discreet manner. It is encouraging to see that the company itself is getting excited about Theratope, as we may be on the verge of graduating from a little Canadian biotech company, to a major player in the arena of cancer vaccines. Biomira has never touted its own horn, or hyped its developments to the investment community. But perhaps we are seeing a hint that the company is confident in Theratope's chances. As a cancer patient quoted in the report said, the company "deserves it!" Looking forward to next week. Good luck! Garry

To: StockMiser who wrote (649)	5/7/1999 10:05:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2344

OT++ This is a listing of the search results from the WSJ site over the last 30 days. Find: Imclone May. 4 TIP SHEET: Amerindo's Slattery Sees Mid-Cap Biotech Surge Apr. 23 Technology Briefs Allou Health & Beauty Care Inc. is expected to announce Friday the sale of a controlling stake in its online unit to an investor group for $37 million in cash and notes. The unit, Fragrance Counter, sells perfume and beauty products online. Allou, a Brentwood, N.Y., distributor of beauty and health-care products, launched its Internet business in 1995. The investor group includes style doyenne Martha Stewart, Allen & Co. managing director Nancy Peretsman, and Laurence Tisch's Loews Corp., according to people familiar with the transaction. Samuel Waksal, a venture capitalist and chief executive of ImClone Systems Inc., a New York biotechnology concern, leads the group. Allou is expected to retain a minority stake. America Online also will have a stake in the company through warrants it holds Apr. 19 Research Reports Apr. 15 SMARTMONEY DAILY SCREEN: Drug Stocks With Momentum Apr. 14 ImClone Systems Cancer Pdt Trials Show Anti-Tumor Activity Apr. 13 ImClone: Antibody Stops New Blood Vessel Growth In Tumors One item, about the CEO, would hardy call for a stampede to IMCL stock. Although it is a quite pleasant to think that he is in business with Martha S. One is from SM Mag.(WSJ related) I had seen at least one other article on them. No real "new medical" stuff but the name was splashed around a bit. Waiting for the pull back. Go BIOM! Jim